Amarin CEO comments on its new medicine's mixed results in its drug trial

12:39 PM ET Mon, 12 Nov 2018

CNBC's Meg Tirrell sits down with Amarin CEO John Thero to discuss Amarin dropping after posting mixed results in a drug trial.